This website is an information resource intended for healthcare professionals only.
Patients who have been given Penthrox® can find the Patient Information Leaflet (PIL) here.
Report adverse events
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of medicine.
Mundipharma routinely monitors the safety of all its medicines, including reviewing safety data from clinical studies and collecting reports of adverse events. If you are a patient or are aware of a patient who has experienced an adverse event, overdose or unexpected benefits with one of our products, please also contact Mundipharma by calling +44 (0) 1223 424 211 or by emailing email@example.com. Mundipharma will only use your details to contact you about your adverse event report.
trauma pain relief enables you to focus on your patient’s injury
Penthrox® is inhaled, it enters the lungs in the form of a vapour and is rapidly transported into the bloodstream, giving a fast onset of analgesic action.
In the STOP! Study, a randomised, double-blind, placebo-controlled trial, the median time to first pain relief with Penthrox® was just 4 minutes (vs. 10 minutes with placebo)2. Because it works so quickly, Penthrox® can help minimise patients’ suffering, in the emergency room and this may also improve patients’ satisfaction.6
vs 10 minutes placebo2
Median time to onset of meaningful pain relief
The STOP! Study was a randomised, double-blind, placebo-controlled, UK trial that investigated the efficacy and safety of Penthrox® for the treatment of acute pain in the emergency department.
The investigators found that Penthrox® significantly reduces pain severity compared to placebo, and concluded:
‘Considering its fast onset of action, ease of use and minimal impact on subsequent treatment choices, methoxyflurane may also lend itself as a bridging agent in the pre-hospital/ED setting until it is possible to administer more powerful analgesia if required.’11
Results of the analysis of VAS Pain Intensity Score (adults ≥18 years)
Historical risk associated with high anaesthetic doses of methoxyflurane
Nephrotoxicity caused by metabolite fluoride, is a dose-related effect associated with high anaesthetic doses3
Analgesic dose Penthrox® significantly lower than anaesthetic dose – at least 6-fold below the upper safety limit3
|Methoxyflurane Penthrox® (1 x 3mL bottle)||0.3|
|Methoxyflurane Upper safety limit||≤2.0|
|Methoxyflurane Subclinical toxicity||2.5-3.0|
|Methoxyflurane Clinical toxicity||>5.0|
|MAC||minimum alveolar concentration, the concentration required to produce surgical anaesthesia in 50% of healthy patients|
|MAC-hour||determined by multiplying the MAC by the duration of administration of anaesthetic|
The STOP! Study found that majority of adverse events are usually mild and transient, the most common being dizziness and headache.1,2,11
Penthrox® has no clinically relevant effects on vital signs and only a low risk associated with respiratory depression1,14
|MedDRA System Organ Class||Common
≥1/100 to <1/10
≥1/1,000 to <1/100
|Metabolism and nutrition disorders||Increased appetite|
|Nervous system disorders||Amnesia
Peripheral sensory neuropathy
|Respiratory, thoracic and mediastinal disorders||Cough|
|Gastrointestinal disorders||Dry mouth
|Skin and subcutaneous tissue disorders||Hyperhidrosis|
|General disorders and administration site conditions||Feeling drunk||Fatigue